Phase I Safety and Immunogenicity Evaluation of MVA-CMDR, a Multigenic, Recombinant Modified Vaccinia Ankara-HIV-1 Vaccine Candidate

HIV-1 Vaccine Development After STEP

(2010) Dan H. Barouch et al.   Annual Review of Medicine

A Phase 1/2 Study of a Multiclade HIV‐1 DNA Plasmid Prime and Recombinant Adenovirus Serotype 5 Boost Vaccine in HIV‐Uninfected East Africans (RV 172)

(2010) Hannah Kibuuka et al.   JOURNAL OF INFECTIOUS DISEASES

Priming Immunization with DNA Augments Immunogenicity of Recombinant Adenoviral Vectors for Both HIV-1 Specific Antibody and T-Cell Responses

(2010) Richard A. Koup et al.   PLoS One

Phase 1 Safety and Immunogenicity Evaluation of ADMVA, a Multigenic, Modified Vaccinia Ankara-HIV-1 B'/C Candidate Vaccine

(2010) Sandhya Vasan et al.   PLoS One

A Phase 1 Study to Evaluate the Safety and Immunogenicity of a Recombinant HIV Type 1 Subtype C-Modified Vaccinia Ankara Virus Vaccine Candidate in Indian Volunteers

(2009) Vadakkuppatu Devasenapathi Ramanathan et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

Safety and Immunogenicity of the Merck Adenovirus Serotype 5 (MRKAd5) and MRKAd6 Human Immunodeficiency Virus Type 1 Trigene Vaccines Alone and in Combination in Healthy Adults

(2009) C. Harro et al.   Clinical and Vaccine Immunology

Broad, high-magnitude and multifunctional CD4+ and CD8+ T-cell responses elicited by a DNA and modified vaccinia Ankara vaccine containing human immunodeficiency virus type 1 subtype C genes in baboons

(2009) W. A. Burgers et al.   JOURNAL OF GENERAL VIROLOGY

T-Cell Vaccine Strategies for Human Immunodeficiency Virus, the Virus with a Thousand Faces

(2009) B. T. Korber et al.   JOURNAL OF VIROLOGY

Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand

(2009) Supachai Rerks-Ngarm et al.   NEW ENGLAND JOURNAL OF MEDICINE

Design and evaluation of multi-gene, multi-clade HIV-1 MVA vaccines

(2009) Patricia L. Earl et al.   VACCINE

Recombinant Modified Vaccinia Ankara (MVA) effectively boosts DNA-primed HIV-specific immune responses in humans despite pre-existing vaccinia immunity

(2009) Lindvi Gudmundsdotter et al.   VACCINE

An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses

(2008) Alexandre Harari et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Broad Immunogenicity of a Multigene, Multiclade HIV‐1 DNA Vaccine Boosted with Heterologous HIV‐1 Recombinant Modified Vaccinia Virus Ankara

(2008) Eric Sandström et al.   JOURNAL OF INFECTIOUS DISEASES

HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case–cohort analysis

(2008) M Juliana McElrath et al.   LANCET

Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial

(2008) Susan P Buchbinder et al.   LANCET

Toward an AIDS Vaccine

(2008) B. D. Walker et al.   SCIENCE

EV01: A phase I trial in healthy HIV negative volunteers to evaluate a clade C HIV vaccine, NYVAC-C undertaken by the EuroVacc Consortium

(2008) Pierre-Alexandre Bart et al.   VACCINE

Lessons from IAVI-006, a Phase I clinical trial to evaluate the safety and immunogenicity of the pTHr.HIVA DNA and MVA.HIVA vaccines in a prime-boost strategy to induce HIV-1 specific T-cell responses in healthy volunteers

(2008) A. Guimarães-Walker et al.   VACCINE

EV02: A Phase I trial to compare the safety and immunogenicity of HIV DNA-C prime-NYVAC-C boost to NYVAC-C alone

(2008) Sheena McCormack et al.   VACCINE

Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa

(2008) Walter Jaoko et al.   VACCINE